Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.58 |
| ▸ | EML4 | Q9HC35 | 7/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 7/20 | 0.53 |
| ▸ | FLT3 | P36888 | 7/20 | 0.53 |
| ▸ | RET | P07949 | 6/20 | 0.53 |
| ▸ | ROS1 | P08922 | 6/20 | 0.53 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16206962 | 0.97 | EGFR (0.62) | EGFREML4ALKFLT3RET | |
| SCHEMBL16206775 | 0.89 | EGFR (0.72) | EGFREML4ALKFLT3RET | |
| SCHEMBL15134678 | 0.89 | EGFR (0.72) | EGFREML4ALKFLT3RET | |
| SCHEMBL16206789 | 0.89 | EGFR (0.72) | EGFREML4ALKFLT3RET | |
| SCHEMBL16206785 | 0.89 | EGFR (0.72) | EGFREML4ALKFLT3RET | |
| SCHEMBL16206786 | 0.85 | EGFR (0.72) | EGFREML4ALKFLT3RET | |
| SCHEMBL16207162 | 0.84 | EGFR (0.82) | EGFREML4ALKFLT3RET | |
| SCHEMBL16207317 | 0.84 | EGFR (0.75) | EGFREML4ALKFLT3RET | |
| SCHEMBL16206988 | 0.83 | EGFR (0.65) | EGFREML4ALKFLT3RET | |
| SCHEMBL16207170 | 0.81 | EGFR (0.87) | EGFREML4ALKFLT3RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9085540-B2 | Pyrazinecarboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-07-21 | — | — | US | disclosed |
| US-9085540-B2 | Pyrazinecarboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-07-21 | — | — | US | disclosed |
| EP-2805940-A1 | PYRAZINE CARBOXAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2014-11-26 | — | — | EP | disclosed |
| US-20140323463-A1 | PYRAZINECARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-10-30 | — | — | US | disclosed |
| US-20140323463-A1 | PYRAZINECARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323463-A1 | PYRAZINECARBOXAMIDE COMPOUND | EGFR, ERBB2, ALK | EGFR 1/4885EML4 158/4885ALK 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.